Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5673067 | 0.98 | SIGMAR1 (0.42) | L3MBTL1MAOASIGMAR1 | |
| SCHEMBL5671669 | 0.88 | GPR52 (0.37) | — | |
| SCHEMBL5671602 | 0.79 | KCNH2 (0.46) | SIGMAR1 | |
| SCHEMBL5674577 | 0.77 | MAOB (0.43) | MAOB | |
| SCHEMBL1478014 | 0.70 | SIGMAR1 (0.52) | L3MBTL1MAOASIGMAR1MAOB | |
| SCHEMBL5038975 | 0.70 | TSHR (0.45) | POLB | |
| SCHEMBL5044078 | 0.70 | KCNA3 (0.44) | — | |
| SCHEMBL11418714 | 0.69 | MAPT (0.46) | MAOASIGMAR1MAOB | |
| SCHEMBL9848958 | 0.69 | MAOB (0.46) | L3MBTL1MAOASIGMAR1MAOB | |
| SCHEMBL9560040 | 0.69 | SIGMAR1 (0.55) | L3MBTL1MAOASIGMAR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115666-B2 | Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain | RENOVIS, INC. (US) | 2006-10-03 | — | — | US | claimed |
| EP-1578717-A4 | NITRONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING INFLAMMATION AND NEUROPATHIC PAIN | RENOVIS INC (US) | 2006-08-09 | — | — | EP | claimed |
| EP-1578717-A2 | NITRONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING INFLAMMATION AND NEUROPATHIC PAIN | Renovis, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| WO-2004034999-A2 | NITRONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING INFLAMMATION AND NEUROPATHIC PAIN | RENOVIS, INC. (US) | 2004-04-29 | — | — | WO | claimed |
| US-7115666-B2 | Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain | RENOVIS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1578717-A4 | NITRONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING INFLAMMATION AND NEUROPATHIC PAIN | RENOVIS INC (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20060100289-A1 | Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain | RENOVIS, INC. | 2006-05-11 | — | — | US | disclosed |
| EP-1578717-A2 | NITRONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING INFLAMMATION AND NEUROPATHIC PAIN | Renovis, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040142983-A1 | Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain | RENOVIS, INC. | 2004-07-22 | — | — | US | disclosed |
| WO-2004034999-A2 | NITRONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING INFLAMMATION AND NEUROPATHIC PAIN | RENOVIS, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100289-A1 | Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain | MMP8, PTGES, NGF | L3MBTL1 4283/4885MAOA 1438/4885SIGMAR1 566/4885 |
| US-20040142983-A1 | Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain | MMP8, PTGES, NGF | L3MBTL1 4283/4885MAOA 1438/4885SIGMAR1 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.